Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large...

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• The positive regulatory domain I (PRDM1) gene is crucial for B-cell differentiation.
• PRDM1 has two isoforms, PRDM1alpha and PRDM1beta, regulated by NF-kappaB.
• PRDM1 expression is observed in aggressive diffuse large B-cell lymphoma (DLBCL) subtypes.

Purpose of the Study:

• To investigate PRDM1 gene expression in DLBCL patients.
• To determine the prognostic significance of PRDM1 isoforms in DLBCL.
• To elucidate the mechanism of rituximab action in DLBCL.

Main Methods:

• Laser microdissection and RT-PCR were used to assess PRDM1 gene expression in 82 DLBCL patients.
• Correlation analysis was performed between PRDM1 expression and patient survival.
• In vitro studies examined PRDM1beta expression in chemotherapy-resistant B-lymphoma cells.

Main Results:

• Both PRDM1alpha and PRDM1beta transcripts were exclusively found in the non-germinal center B-cell-like (non-GCB) DLBCL subtype.
• PRDM1beta expression correlated with shorter survival in non-GCB DLBCL patients treated with CHOP chemotherapy.
• Rituximab treatment suppressed PRDM1beta expression and inactivated NF-kappaB in vitro.

Conclusions:

• PRDM1beta may serve as a prognostic marker in non-GCB DLBCL.
• Rituximab demonstrates efficacy against DLBCL by downregulating PRDM1beta and NF-kappaB.
• This study enhances understanding of rituximab's biological effects in DLBCL treatment.